Sleep timing, blood sugar control, and heart health in adults with type 1 diabetes
Circadian Mechanisms of Glycemic Control and Cardiovascular Risk in Adults with Type 1 Diabetes
This project looks at whether making sleep longer and more regular helps adults with type 1 diabetes keep blood sugar steadier and reduce heart disease risk.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Illinois at Chicago NIH-funded |
| Lab location | 1 site (Chicago, UNITED STATES) |
| Project ID | NIH-11190878 on NIH RePORTER |
What this research studies
You would track your sleep and blood sugar while researchers measure blood pressure patterns and sleep-related hormones. Participants may wear a sleep monitor and a continuous glucose monitor, give urine or blood samples for melatonin metabolites, and have 24-hour blood pressure measurements. The team will offer a behavioral program to lengthen and regularize sleep and compare glucose control and cardiovascular risk markers before and after the program. The approach aims to show how improving sleep could lead to safer blood sugars and lower heart disease risk for people with T1D.
Who could benefit from this research
Good fit: Adults (about 21 years and older) living with type 1 diabetes, especially those with short, irregular, or poor-quality sleep, are ideal candidates.
Not a fit: People without type 1 diabetes or those who already have regular, sufficient sleep are unlikely to gain direct benefit from this specific project.
Why it matters
Potential benefit: If successful, this work could show that simple sleep changes help people with T1D manage glucose better and lower their cardiovascular risk.
How similar studies have performed: Earlier pilot studies and trials have shown that behavioral sleep interventions can improve sleep regularity and time spent in target glucose range, though the links to cardiovascular risk remain to be clarified.
Where this research is happening
Chicago, UNITED STATES
- University of Illinois at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Martyn-Nemeth, Pamela Ann — University of Illinois at Chicago
- Study coordinator: Martyn-Nemeth, Pamela Ann
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.